About Us
Shannon Traphagen
Also known as S.M. Traphagen, Shannon is the host and creator of The Game On Glio Podcast – a podcast that is truly her passion and drive as she continues to be an advocate and storyteller for those walking through brain cancer, grief and loss. She is also the founder of Traphagen’s Trail Ride 4 Brain Cancer.
With several years experience as a radio personality, speaker, and host, she also has experience in television, writing, social media and marketing. Shannon’s novel FINDING MORGAN: A LEFAY TRILOGY has received 5-star reviews, along with her highly rated blog Grace. Guidance. Gratitude. When Shannon is not hosting The Game On Glio Podcast, she does public speaking engagements, runs her fundraiser Traphagen’s Trail Ride 4 Brain Cancer, handles marketing projects for global clients, is a guest for book club Q&A’s, and is currently finishing writing Book 2 in the LEFAY TRILOGY. For her blogs and current writing or speaking work, visit her website smtraphagen.com
If you’d like to inquire about marketing services or podcast sponsorships, contact her at writelifemediamarketing@gmail.com, gameongliopodcast@gmail.com or via Instagram.
Kevin T. Minorczyk
Kevin is a highly experienced media producer in Buffalo, NY. Working primarily in radio, podcast, and television production, his experience extends to print and web advertising, with specialties in editing and visual effects. He is also involved in the 48 Film Project-Buffalo, each year, churning out quality film projects within 48 hours!
Gamma Tile/GT Medical Technologies

Season 2 Sponsor
Mimivax LLC
Formed in 2012, Mimivax LLC is a clinical-stage biotechnology company that develops immunotherapeutic vaccines and therapies for treatment of cancers such as glioblastoma. Learn more at mimivax.com
OncoSynergy, Inc.
OncoSynergy is a physician-led, clinical-stage immuno-oncology company on a mission to dramatically improve outcomes for patients suffering from the worst cancers. OncoSynergy’s lead therapeutic, OS2966, is currently being evaluated in a Phase 1 trial for the treatment of recurrent glioblastoma. OS2966 is an antibody that blocks cell surface receptors that govern fundamental biological processes that allow cancer cells to grow, spread and become resistant to cancer treatment. Successful treatments of glioblastoma has been limited by the presence of the brain’s protective blood brain barrier (BBB). To overcome this obstacle, a technique called convection-enhanced-delivery (CED) is utilized to deliver OS2966 directly to the site of disease. Convection-enhanced delivery involves placement of one or more catheters into the brain in order to slowly infuse a therapy into the tissue. To be eligible for this study participants must require surgical resection of their recurrent glioblastoma. Learn more at oncosynergy.com